Am­gen to buy Hori­zon for $28B; Mer­ck, Mod­er­na tout can­cer vac­cine; FDA ap­proves sec­ond KRAS drug; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We’re tak­ing a hia­tus next week as the lights go out at End­points for the end-of-year hol­i­day, but will re­turn to your in­box on Dec 31, a Sun­day, to re­cap any news over the next two weeks. Thank you so much for your read­er­ship in 2022. End­points Week­ly be­gan al­most two years ago with a blank slate and now has close to 70,000 sub­scribers. Hap­py hol­i­days!

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER